Plasma Fractionation Market Size, Share, Growth, and Industry Analysis, By Types (Albumin, Immunoglobulins, Coagulation Factor Concentrates, Others), By Applications Covered (Hospitals, Clinics, Academic Institutes, Clinical Research Laboratories) and Regional Insights and Forecast to 2033

Plasma Fractionation Market Size

The Global Plasma Fractionation Market size stood at USD 30,420 million in 2024 and is projected to reach USD 32,731.92 million in 2025, eventually surging to USD 58,812.51 million by 2033. This remarkable growth reflects a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2025 to 2033. The expansion is primarily driven by increasing demand for immunoglobulins, albumin, and coagulation factors across hospitals and specialty clinics. The Global Plasma Fractionation Market is witnessing significant uptake in developed and developing countries due to rising geriatric populations and the growing incidence of rare and chronic diseases.

The US Market is contributing prominently to this growth, with rising cases of immunodeficiency disorders, improved healthcare infrastructure, and strategic investments in plasma collection centers boosting overall market development.

Key Findings

• Market Size - Valued at 32731.92M in 2025, expected to reach 58812.51M by 2033, growing at a CAGR Of 7.6%.
• Growth Drivers - Immunoglobulins account for 48% of usage; hospitals contribute 45% of demand globally.
• Trends - 31% of facilities using single-use technologies; 22% of companies pursuing recombinant-plasma integration.
• Key Players - Takeda, CSL, Grifols, Octapharma, Kedrion.
• Regional Insights - North America leads with 38% share, followed by Europe at 29%, Asia-Pacific at 24%, and Middle East & Africa at 9%, reflecting global demand driven by healthcare infrastructure and plasma collection capabilities.
• Challenges - Plasma donation rates dropped by 14%; 37% of institutions report high infrastructure cost barriers.
• Industry Impact - 36% of M&A activity linked to plasma; 28% of investment in automation and safety systems.
• Recent Developments - 22% rise in new therapies launched; 17% boost in manufacturing capacity through expansions.

The Plasma Fractionation Market is an essential segment of the biopharmaceutical industry, offering life-saving plasma-derived therapies for various critical conditions. Plasma fractionation refers to the separation of plasma into individual components such as immunoglobulins, albumin, and clotting factors. These components are vital in treating patients with immune deficiencies, bleeding disorders, liver diseases, and various neurological and autoimmune conditions. The Global Plasma Fractionation Market is expanding rapidly due to growing awareness about plasma therapies, advancements in purification techniques, and increasing clinical usage of plasma derivatives. Rising healthcare expenditure and the growing need for effective therapies for chronic conditions have made plasma fractionation a critical area of medical research and pharmaceutical innovation. The segment is also gaining momentum due to the rising number of surgical procedures that require plasma-derived products for effective blood volume replacement. Demand for intravenous immunoglobulin (IVIG) and alpha-1 antitrypsin is accelerating due to their effectiveness in treating primary immunodeficiency diseases and genetic respiratory disorders. The growing elderly population, which is more susceptible to such conditions, is expected to further fuel demand. Additionally, continuous R&D efforts and innovation in fractionation technologies, such as chromatography and nanofiltration, are enhancing product safety, efficacy, and yields. This has opened new avenues for expansion, especially in emerging healthcare markets.

Plasma Fractionation Market Trends

The Plasma Fractionation Market is experiencing several notable trends driven by evolving therapeutic demand and innovation in processing technologies. Over 48% of the market demand is accounted for by immunoglobulin applications, reflecting a growing reliance on IVIG for treating immune system disorders. Approximately 26% of the plasma fractionation demand is linked to albumin, primarily used in liver disease, burns, and shock treatments. Furthermore, clotting factor concentrates constitute around 17% of the market, with Factor VIII and IX witnessing steady utilization for hemophilia treatment. Hospitals represent nearly 45% of the end-use segment share due to increased plasma-based therapeutic administration during surgeries and trauma care. The pharmaceutical and biotechnology sector follows closely with a 38% share, focusing on product development and expansion of therapeutic indications. Notably, over 31% of plasma fractionation processing facilities are now employing single-use technologies and automation to improve sterility and reduce cross-contamination risks. Europe and North America together hold nearly 60% of the total market volume, driven by well-established healthcare frameworks and increased donations through organized blood plasma collection networks. Meanwhile, Asia-Pacific is emerging as a growth hotspot with over 19% share, fueled by rising awareness, improving infrastructure, and supportive government programs encouraging plasma donation and storage.

Plasma Fractionation Market Dynamics

DRIVERS

Rising Demand for Immunoglobulin-Based Therapies

Over 48% of the plasma-derived therapies demand is driven by immunoglobulin usage due to increasing autoimmune disorders and primary immunodeficiency diseases. The geriatric population contributes to nearly 32% of global plasma-based treatment cases. With rising awareness and diagnosis, hospitals have observed a 41% increase in immunoglobulin-based prescriptions for chronic illnesses. Additionally, over 52% of the demand in North America is contributed by immunoglobulins, with neurological and hematological treatments accounting for a growing portion.

OPPORTUNITY

Growth in Emerging Healthcare Infrastructure and Plasma Collection Programs

Asia-Pacific holds nearly 19% of the Plasma Fractionation Market, and this is projected to rise due to growing healthcare investments and awareness campaigns. In emerging markets, over 36% of blood banks are expanding plasma collection capacity. India and China are investing in modernizing nearly 40% of their existing plasma centers. In Latin America, around 21% of newly licensed blood establishments are incorporating fractionation capabilities, opening avenues for domestic therapy production and reducing reliance on imports.

RESTRAINTS

"High Cost and Complex Infrastructure"

Plasma fractionation requires highly specialized facilities and regulatory-compliant environments. Around 45% of companies report high operational expenses due to stringent safety, filtration, and purification processes. Nearly 33% of the emerging market players struggle with infrastructure development and licensing delays. Setting up a compliant plasma fractionation plant can require regulatory testing timelines extending up to 24 months. The technical complexity restricts new entrants, which limits supply and scalability in cost-sensitive regions. Additionally, 37% of healthcare institutions in low-income regions lack access to affordable plasma-derived therapies.

CHALLENGE

"Rising Costs and Donor Supply Shortages"

Plasma collection is highly dependent on voluntary donors, but globally, only 41% of eligible populations participate in donation programs. In the U.S., donation frequency dropped by nearly 14% in recent quarters due to regulatory tightening and donor fatigue. Europe witnessed a 17% decline in plasma availability due to pandemic-related restrictions. Over 28% of manufacturers report disruptions in supply chains due to irregularities in plasma procurement. This supply gap creates significant cost pressures and hinders consistent product availability, especially in regions relying on imports.

Segmentation Analysis

The Plasma Fractionation Market is segmented by type and application, each playing a vital role in shaping therapeutic strategies across healthcare settings. The type segment includes Albumin, Immunoglobulins, Coagulation Factor Concentrates, and Others. Immunoglobulins account for the largest demand due to their extensive usage in immunodeficiencies and autoimmune diseases. On the other hand, albumin has seen increased adoption in liver disease and trauma cases. Based on application, hospitals dominate due to high plasma therapy usage during surgeries, intensive care, and emergency services. Clinics, academic institutes, and clinical research laboratories contribute significantly to the evolving applications in diagnostics, teaching, and investigational use of plasma-derived components.

By Type

• Albumin: Albumin comprises nearly 26% of the total plasma product usage, majorly in burn and shock treatments. It is widely used for restoring blood volume and stabilizing patients during surgical recovery.
• Immunoglobulins: Accounting for 48% share, immunoglobulins are the most demanded plasma fractionation output. Used in immunodeficiency and neurological treatments, its administration in chronic conditions has surged across North America and Europe.
• Coagulation Factor Concentrates: Around 17% of the market involves clotting factor concentrates, notably Factor VIII and IX, which are crucial for hemophilia management and post-operative care in trauma patients.
• Others: This segment includes alpha-1 antitrypsin and C1 esterase inhibitors, covering roughly 9% of the market. Their applications are expanding in genetic and rare condition treatments, primarily in specialized care centers.

By Application

• Hospitals: Hospitals dominate with over 45% application share, owing to continuous use in emergency surgeries, transfusion needs, and specialized therapies for critical care patients.
• Clinics: Clinics contribute 22% to the total applications, focusing on long-term immunoglobulin administration and chronic disease outpatient care, particularly in developed regions.
• Academic Institutes: Nearly 14% of plasma fractionation products are used in academic and teaching settings, supporting education on hematology and clinical immunology through real-world clinical sample analysis.
• Clinical Research Laboratories: Approximately 19% of demand stems from clinical research labs leveraging plasma derivatives in pharmacological testing, disease modeling, and drug validation studies.

Plasma Fractionation Market Regional Outlook

The Plasma Fractionation Market exhibits a distinct regional distribution, with North America leading due to robust healthcare infrastructure, followed by Europe, Asia-Pacific, and the Middle East & Africa. North America accounts for 38% of the total market share, primarily due to high plasma collection rates and increased immunoglobulin demand. Europe holds 29%, driven by extensive government-funded blood networks and research institutions. Asia-Pacific contributes 24%, backed by improving healthcare systems and rising awareness about plasma therapies. The Middle East & Africa represents 9%, where government initiatives and collaborations with international health bodies are helping to expand accessibility to plasma-derived products across underserved regions.

North America

North America dominates the Plasma Fractionation Market with a 38% share, supported by a mature regulatory environment and a high concentration of top manufacturers. The U.S. alone performs over 60% of global plasma donations. Nearly 54% of plasma-derived product consumption in North America is for immunoglobulins used in chronic neurological and autoimmune conditions. Plasma collection volumes increased by 16% year-on-year in the U.S., with the country hosting over 1,000 plasma donation centers. Canada is also witnessing a steady rise in plasma product utilization across academic hospitals and specialized clinics.

Europe

Europe contributes 29% of the global plasma fractionation demand, driven by robust public-private partnerships and national blood services. Germany, France, and the UK account for over 67% of Europe’s share. Immunoglobulin therapies comprise 49% of the regional usage, while albumin follows at 27%, particularly for hepatic and trauma cases. Over 35% of the European plasma centers now operate with fully automated fractionation technologies. Additionally, the region has implemented efficient patient access programs, increasing plasma therapy usage in over 18 countries.

Asia-Pacific

Asia-Pacific holds a 24% share in the global plasma fractionation space, driven by growing healthcare investments and increasing adoption of plasma-based therapies. China and India together account for more than 63% of this regional market. Over 40% of plasma therapy applications are for treating hemophilia and liver cirrhosis. Japan and South Korea are rapidly scaling up plasma processing technologies, contributing 29% of the region’s total production. Local manufacturing expansion is helping reduce reliance on imports by more than 20% in emerging economies.

Middle East & Africa

The Middle East & Africa holds a 9% share of the market, supported by policy reforms and expanding healthcare access. Saudi Arabia, UAE, and South Africa are the largest contributors in the region, with 47% of the market share combined. Around 33% of the regional plasma usage is directed toward trauma care and intensive care units. International collaborations have helped increase plasma collection by 19% in key urban regions. While infrastructure challenges remain, demand is growing at academic and tertiary-care hospitals.

List of Key Plasma Fractionation Market Companies Profiled

Investment Analysis and Opportunities

Investment activity in the Plasma Fractionation Market is intensifying, particularly in emerging regions and product innovation. Nearly 42% of global investments are currently focused on expanding plasma collection infrastructure and building decentralized processing centers. Over 28% of recent investments have gone into automation and nanofiltration technologies to improve yields and reduce cross-contamination. In Asia-Pacific, local production initiatives backed by public-private partnerships account for 19% of total investment flow. More than 36% of M&A deals in the life sciences sector in the last 12 months were related to plasma-derived therapy providers. Countries like China, India, and Brazil have witnessed a 27% increase in foreign direct investment for setting up plasma manufacturing facilities. With 33% of companies allocating new R&D budgets to plasma innovation, the industry is poised to scale up both in volume and therapeutic reach.

New Products Development

The Plasma Fractionation Market is witnessing rapid development of novel therapies and advanced formulations. Around 39% of newly launched plasma products are targeted at neurological and autoimmune diseases. Recombinant technologies are gaining traction, with 22% of global manufacturers integrating hybrid production systems combining recombinant proteins and plasma derivatives. In Europe, 31% of new drug approvals in the last year included plasma-based therapies or biosimilars. Companies are also expanding into subcutaneous immunoglobulin formats, which now account for 18% of the product pipeline. Enhanced purification techniques such as affinity chromatography are now used in over 45% of new developments. Additionally, dual-indication therapies—capable of treating multiple rare diseases—are being explored, representing 13% of all pipeline assets in the segment. These innovations are expected to improve patient compliance and reduce infusion times by 29%, which will significantly support patient-centric care models.

Recent Developments

• Grifols Expanded U.S. Plasma Centers: Grifols opened 20 new plasma donation centers in the U.S., increasing its capacity by 15% and improving regional supply chains.
• CSL Introduced New IVIG Therapy: CSL launched a new high-purity intravenous immunoglobulin product, covering 12% of total immunoglobulin demand across multiple countries.
• Takeda Invested in Swiss Plasma Facility: Takeda allocated new funding toward upgrading its plasma fractionation plant in Switzerland, boosting processing capabilities by 17%.
• Octapharma Developed Dual-Use Albumin Formulation: Octapharma released a dual-indication albumin product for liver and burn patients, projected to address 10% of clinical use cases.
• Kedrion Opened R&D Facility in Italy: Kedrion inaugurated a new plasma research hub focused on immunoglobulin innovation, aimed at increasing output by 22% annually.

Report Coverage

The Plasma Fractionation Market report offers in-depth insights into market segmentation, regional distribution, competitive dynamics, investment trends, and recent product developments. The report analyzes key types including albumin, immunoglobulins, and coagulation factors, while highlighting applications across hospitals, clinics, research labs, and academic institutes. It details the top contributing regions, led by North America (38%), Europe (29%), Asia-Pacific (24%), and the Middle East & Africa (9%). The study includes company profiles, technological innovations, challenges, and evolving market strategies. Approximately 48% of demand is driven by immunoglobulins, followed by albumin at 26% and clotting factors at 17%. Hospitals account for 45% of total application use. The report also evaluates the impact of automation, regulatory trends, and emerging product formats, giving stakeholders data-driven direction for strategy and expansion.